Company: MIRM
Filing Date: 2025-12-08
Form Type: 8-K
Source: 0001193125-25-310611
Chunk: 1

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-12-08
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01      Regulation FD Disclosure.  

On December 8, 2025, the Company issued a press release announcing its entry into the Merger Agreement and the Subscription Agreement, a copy of which is furnished as Exhibit 99.1 to this Form8-K. In connection with the Private Placement, the Company presented a corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Form8-K.

As provided in General Instruction B.2 of Form8-K, the information in this Item 7.01, including Exhibits 99.1 and 99.2 hereto, shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities under, Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information or Exhibits 99.1 and 99.2 be deemed to be incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

  Item 8.01      Other Events.  

The press release attached hereto as Exhibit 99.1 and the corporate presentation attached hereto as Exhibit 99.2 contain information relating to anticipated developments concerning the Company’s business and include the following disclosures:

Company Update

Assuming the Closing of the proposed Mergers, which the Company anticipates will occur in the first quarter of 2026, subject to regulatory approval and satisfaction or waiver of other customary closing conditions, the Company will acquire worldwide rights to brelovitug, an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 monoclonal antibody that is intended to target the surface antigen (“ HBsAg”) on both the chronic hepatitis D virus (“ HDV”) and the chronic hepatitis B virus (“ HBV”). Target has designed brelovitug to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles. Brelovitug for the treatment of chronic HDV has received breakthrough therapy designation from the U. S. Food and Drug Administration (“ FDA”), designation under the Priority Medicines (PRIME) scheme from the European Medicines Agency (“ EMA”) and an orphan medicinal product designation by the European Commission. Target’s in-licensedcomposition of matter patent for brelovitug expires July 2041, subject to a